Anetumab ravtansine
Anetumab ravtansine (pronunciation: a-net-u-mab rav-tan-sine) is a biopharmaceutical drug used in the treatment of certain types of cancer. It is an antibody-drug conjugate (ADC) that combines an antibody specific to the mesothelin protein with a potent cytotoxic agent, ravtansine.
Etymology
The name "Anetumab ravtansine" is derived from the components of the drug. "Anetumab" refers to the antibody component, which is specific to the mesothelin protein. "Ravtansine" refers to the cytotoxic agent that is conjugated to the antibody.
Mechanism of Action
Anetumab ravtansine works by binding to the mesothelin protein on the surface of cancer cells. Once bound, the drug is internalized by the cell, where the cytotoxic agent ravtansine is released. This agent interferes with the cell's ability to divide and grow, leading to cell death.
Related Terms
See Also
External links
- Medical encyclopedia article on Anetumab ravtansine
- Wikipedia's article - Anetumab ravtansine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski